Organization | Allife Medical Science and Technology Co., Ltd.

Allife Medical Science and Technology Co., Ltd. Report issue

For profit Phase 1

Founded: Beijing China (2018)

Organization Overview

First Clinical Trial

2018

NCT03559764

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Allife Medical Science and Technology Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (12)

anti-psma car nk cells (1 trial)

autologous cd19/cd22 chimeric antigen receptor t-cells (1 trial)

autologous dendritic cells (1 trial)

autologous mesenchymal stem cell-derived neural progenitors (1 trial)

autologous natural killer cells (1 trial)

bcma car-t cells (1 trial)

cd19 car-t cells (2 trials)

cd22 car-t cells (1 trial)

dc-cik cells (1 trial)

mesothelin car t cells (1 trial)

Neural Stem Cell-Derived Neurons (1 trial)

pembrolizumab (keytruda) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Ovarian Epithelial (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Ovarian Neoplasms (Phase 1)

Parkinson Disease (Phase 1)

Prostatic Neoplasms (Phase 1)

Stroke (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 11
# of Trial APIs: 12